Pregna Eloira LNG IUS contraceptive

The LNG IUS contraceptive was developed in the 1970s by Population Council. It consists of a T-shaped plastic frame and white cylinder shaped hormone reservoir around the vertical arm of the frame, with two nylon threads for removal. The system contains 52 mg of the hormone levonorgestrel and releases approx. 20µg/24h in the uterus for up to five years of protection

₹ 2,625.00 2625.0 INR ₹ 2,625.00

₹ 2,500.00

Not Available For Sale

    This combination does not exist.

    Terms and Conditions
    30-day money-back guarantee

    Shipping: 2-3 Business Days

    Eloira - LNG IUS is made of flexible plastic

    Eloira contains a progestin hormone called levonorgestrel which has been used in birth control pills since the 1970s

    The safety of levonorgestrel has been proven by clinical use also in sub-dermal implants and intrauterine systems since decades

    Effective rate of unplanned pregnancy ~0.2% at 1year and less than 1% at 5 years
    High continuation rate: up to 85% at one year  
    Significantly reduces menstrual blood loss
    No impact on return to fertility after removal (80% at 1 year) 

    A woman may choose to use eloira if she:
    Wants contraception that provides a low chance of getting pregnant 
    Wants contraception that is reversible
    Wants a contraceptive method that does not require taking it daily
    Wants treatment for heavy periods and is willing to use a contraceptive method that is placed in the uterus to prevent pregnancy and a copper IUD would not be appropriate

    Indications for use
    Dysfunctional Uterine Bleeding
    Endometrial Hyperplasia

    Alternative to Sterilization
    Where sterilization services are not available or not acceptable, IUS is as effective as sterilization (8 vs. 13 failures per 1000 procedures at 5 years)
    Reversibility of LNG IUS reduces risk of regret
    Complementing female sterilization in northern Europe

    Treatment for HMB
    Use of LNG IUS makes periods lighter, shorter and less painful (and may include dysmenorrhea)
    Over 12 months, blood loss reduced by 80-96% in women with menorrhagia
    Clinical improvement in associated anemia: Hemoglobin levels rise 1.8g/L in one year of use with LNG IUS, compared to a decrease of 1.2g/L with Copper-T.
    Irregular bleeding or spotting common in first 3-6 months; 20% with amenorrhea at 12 months. Sometimes the amenorrhea rate can be higher than 20% e.g. up to 50% at 12 and 24 months of use